Metyos Secures €2.3M to Pioneer CKD Biowearable

The startup aims to revolutionize chronic kidney disease management through real-time monitoring and remote patient care.

Metyos, a Paris-based medtech startup, has raised €2.3 million in pre-seed funding to develop a biowearable device for monitoring chronic kidney disease (CKD).
The wearable sensor, designed as an arm-worn patch, aims to provide real-time data on CKD biomarkers to both doctors and patients, facilitating remote disease management.
Co-founded by Alexandre Boulanger and Olga Chashchina, Metyos focuses on improving health outcomes for CKD patients and reducing healthcare costs through remote biological monitoring.
The startup targets regulatory approval by the end of 2025 and aims to initially focus on end-stage patients with hyperkalemia, with plans to extend its scope to earlier stage patients.
Metyos distinguishes itself in the biowearable market with its focus on CKD, competing with startups like Biolinq, Alio, and Renalyse, but offering real-time data instead of relying on at-home blood draws.